期刊论文详细信息
JOURNAL OF PAIN 卷:15
Systemic Administration of Propentofylline, Ibudilast, and (+)-Naltrexone Each Reverses Mechanical Allodynia in a Novel Rat Model of Central Neuropathic Pain
Article
Ellis, Amanda1  Wieseler, Julie1  Favret, Jacob1  Johnson, Kirk W.2  Rice, Kenner C.3,4  Maier, Steven F.1  Falci, Scott5  Watkins, Linda R.1 
[1] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA
[2] Medicinova, San Diego, CA USA
[3] NIDA, Chem Biol Res Branch, Rockville, MD USA
[4] NIAAA, NIH, Rockville, MD 20852 USA
[5] Craig Hosp, Englewood, CO USA
关键词: Avulsion;    toll-like receptor 4;    D-naltrexone;    glia;    pain;   
DOI  :  10.1016/j.jpain.2013.12.007
来源: Elsevier
PDF
【 摘 要 】

Central neuropathic pain (CNP) is a debilitating consequence of central nervous system damage for which current treatments are ineffective. To explore mechanisms underlying CNP, we developed a rat model involving T13/L1 dorsal root avulsion. The resultant dorsal horn damage creates bilateral below-level (L4-L6) mechanical allodynia. This allodynia, termed spinal neuropathic avulsion pain, occurs in the absence of confounding paralysis. To characterize this model, we undertook a series of studies aimed at defining whether spinal neuropathic avulsion pain could be reversed by any of 3 putative glial activation inhibitors, each with distinct mechanisms of action. Indeed, the phosphodiesterase inhibitor propentofylline, the macrophage migration inhibitory factor inhibitor ibudilast, and the toll-like receptor 4 antagonist (+)-naltrexone each reversed below-level allodynia bilaterally. Strikingly, none of these impacted spinal neuropathic avulsion pain upon first administration but required 1 to 2 weeks of daily administration before pain reversal was obtained. Given reversal of CNP by each of these glial modulatory agents, these results suggest that glia contribute to the maintenance of such pain and enduring release of macrophage migration inhibitory factor and endogenous agonists of toll-like receptor 4 is important for sustaining CNP. The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens. Perspective: CNP that develops after trauma is often described by patients as severe and intolerable. Unfortunately, current treatments are not effective. This work suggests that using pharmacologic treatments that target glial cells could be an effective clinical treatment for CNP. (C) 2014 by the American Pain Society. Published by Elsevier Inc. All rights reserved

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jpain_2013_12_007.pdf 2269KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:0次